[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100599224":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":10,"locations":10,"responsibleParty":15,"collaborators":19,"id":25,"slug":26,"hasResults":27,"nctId":28,"briefTitle":29,"officialTitle":29,"acronym":10,"eligibilityCriteria":30,"healthyVolunteers":31,"sex":32,"minAge":33,"maxAge":10,"enrollmentInfo":34,"targetDuration":10,"studyType":37,"phases":10,"briefSummary":38,"conditions":39,"keywords":50,"overallStatus":52,"whyStopped":10,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":10},{"fullName":5,"class":6},"The Cleveland Clinic","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Healthy Volunteer",null,"Subjects without cardiovascular disease",{"label":13,"type":10,"description":14,"interventionNames":10},"Cardiovascular Disease Patients","Patients with known or suspected cardiovascular disease",{"type":16,"investigatorFullName":17,"investigatorTitle":18,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Christopher Nguyen","Director of Cardiovascular Innovation Research Center",[20,23],{"name":21,"class":22},"National Institutes of Health (NIH)","NIH",{"name":24,"class":22},"National Heart, Lung, and Blood Institute (NHLBI)","100599224","longitudinal-validation-of-circ-technologies-100599224",false,"NCT07081711","Longitudinal Validation of CIRC Technologies","Inclusion Criteria:\n\n* Age ≥ 18 years of age\n* Provision of written informed consent\n\nExclusion Criteria:\n\n* Vulnerable populations will be excluded from this study including Prisoners\n* Other contraindications to CMR imaging to be determined by standard MRI protocols\n* Decisionally impaired (e.g., dementia or cognitive disability)",true,"ALL","18 Years",{"count":35,"type":36},1000,"ESTIMATED","OBSERVATIONAL","Cardiovascular disease is the leading cause of death worldwide. Advanced cardiovascular imaging using Magnetic Resonance Imaging (MRI) has proven to be effective in providing gold standard myocardial tissue characterization. Moreover, the intrinsic advantage of MRI's lack of exposure to ionizing radiation is particularly beneficial. At the same time, blood work can be very useful in early detection of certain cardiomyopathy, such as amyloid. However, there is a lack of agreement of on which markers are the most sensitive. This multi-study will allow the unique opportunity to form a more comprehensive understanding for various cardiovascular diseases.\n\nThe study team has developed novel cardiac MRI techniques that leverages endogenous tissue properties to reveal a milieu of deep tissue phenotypes including myocardial inflammation, fibrosis, metabolism, and microstructural defects. Among these phenotypes, myocardial microstructure has proven to be most sensitive to early myocardial tissue damage and is predictive of myocardial regeneration. In this study, the investigators aim to further study the importance of cardiac microstructure revealed by MRI in patient and healthy population and compare this novel technology with conventional clinical biomarkers.",[40,41,42,43,44,45,46,47,48,49],"Cardiovascular Diseases","Heart Failure","Ischemic Heart Disease","Non-ischemic Cardiomyopathy","Valvular Heart Disease","Metabolic Cardiomyopathy","Congenital Heart Disease","Aortic Diseases","Atrial Fibrillation","Ventricular Fibrillation",[51],"MRI","NOT_YET_RECRUITING","2026-03-19",{"date":55,"type":56},"2026-03-23","ACTUAL",{"date":58,"type":36},"2026-04",{"date":60,"type":36},"2037-08",{"name":5,"class":6}]